CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Henry Ford Health System
Study ID
NCT05718791
Status
Recruiting
Apply to this trial

Conditions

  • GVHD,Acute

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • blood sample — DIAGNOSTIC_TEST
    blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant

Study Details

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

Key Dates

Start date
May 10, 2023
Status verified
Apr 2026
Primary completion
Dec 30, 2027
Completion
Dec 30, 2027

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

predictors of acute GVHD [ Time Frame: CXCL9 combined with EASIX calculated at day 28 +/- 2 post SCT can be used as predictors of acute GVHD by day 100. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Henry Ford Health SystemDetroitMichigan48202
shatha farhan
[email protected]
313-916-5002

Find similar trials in Detroit, MI

By research site
Henry Ford Health System· Detroit, MI

Related Studies